Bart B Ia, Larina V N, Dergunova E N
Ter Arkh. 2001;73(1):49-52.
To evaluate results of long-term outpatient use of caposide in patients with cardiac failure.
74 patients (59 males and 15 females aged 40-76 years) with chronic cardiac failure (CCF) received caposide in individual doses. CCF was caused by ischemic heart disease (IHD) and dilated cardiomyopathy in 65 and 9 patients, respectively. The treatment effect was assessed by changes in clinical symptoms, quality of life and physical activity.
Clinical symptoms, functional class of IHD, exercise tolerance and quality of life improved. Serious side effects were absent.
Caposide can be considered as first-line therapy in outpatient treatment of patients with CCF of different severity as monotherapy and adjuvant in combined treatment.
评估长期门诊使用卡泊苷治疗心力衰竭患者的效果。
74例慢性心力衰竭(CCF)患者(59例男性和15例女性,年龄40 - 76岁)接受个体化剂量的卡泊苷治疗。CCF分别由缺血性心脏病(IHD)和扩张型心肌病引起,其中65例由IHD引起,9例由扩张型心肌病引起。通过临床症状、生活质量和体力活动的变化评估治疗效果。
临床症状、IHD功能分级、运动耐量和生活质量均有改善。未出现严重副作用。
卡泊苷可被视为不同严重程度CCF患者门诊治疗的一线疗法,可作为单一疗法及联合治疗中的辅助疗法。